PROLONG

Showing 1 posts of 1 posts found.

AMAG Pharmaceuticals’ shares fall 21% after failed Makena trial

March 11, 2019
Sales and Marketing AMAG Pharmaceuticals, Makena, PROLONG, birth, trials

AMAG Pharmaceuticals’ Makena (hydroxyprogesterone caproate) has failed to meet its co-primary endpoints in a trial of patients with a history …

The Gateway to Local Adoption Series

Latest content